Fig. 3

Crossover analysis with Kaplan–Meier survival curves and the log-rank (Mantel-Cox) test. a BRAF^V600E vs. BRAF^non-V600E (51.394 vs. 89.958, Chi-Square 1.130, P = 0.288); b BRAF^V600E & IDH1/2^WT vs. BRAF^non-V600E & IDH1/2^WT (44.500 vs. 93.821, Chi-Square 0.007, P = 0.935); c BRAF^V600E & IDH1/2^WT vs. BRAF^non-V600E & IDH1/2^WT with mutations in G-loop (44.500 vs. 12.250, Chi-Square 0.122, P = 0.727); d BRAF^V600E & IDH1/2^WT vs. BRAF^non-V600E & IDH1/2^WT with mutations in activation segment (44.500 vs. 34.800, Chi-Square 0.145, P = 0.703); e BRAF^non-V600E & IDH1/2^WT with mutations in G-loop vs. the rest BRAF^non-V600E & IDH1/2^WT patients (12.250 vs. 95.100, Chi-Square 0.008, P = 0.927)